Jump to content


The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML),

  • Please log in to reply
2 replies to this topic

#1 WoofWoof


    New Member

  • Members
  • Pip
  • 1 posts

Posted 04 September 2012 - 04:30 PM


I have cancer but it doesn't have me

#2 Trey


    Advanced Member

  • PS Beta Group
  • PipPipPip
  • 1,705 posts
  • LocationSan Antonio, Texas

Posted 04 September 2012 - 04:58 PM

It will be most like Sprycel since it inhibits the SRC kinases as well as BCR-ABL, along with other off-target kinases.  Pleural effusion will be an issue.  There was early hope that Bosutinib would have a much better side effects profile, but that has not been demonstrated in the clinical trials.  But as with all CML drugs, it is different, so the side effects will be different.  The best thing is that it provides one more option for overcoming some forms of drug resistance and allows trading of side effects.  It does NOT work against T315i.


#3 TeddyB


    Advanced Member

  • Members
  • PipPipPip
  • 203 posts

Posted 05 September 2012 - 04:52 AM

Great news, approval of a new drug to help fight our disease.

Any information on when it will be approved in Europe?

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users